The role of retroperitoneal surgery in testis cancer

Robot-assisted Laparoscopic Retroperitoneal Lymph Node Dissection for Testicular Cancer: Evolution of the Technique

BACKGROUND

Retroperitoneal lymph node dissection (RPLND) is an accepted staging and treatment option for nonseminomatous germ cell tumor. Robotic surgery offers technical advantages and is being increasingly used in urologic procedures.

OBJECTIVE

To determine the feasibility and safety of robotic surgery for RPLND.

DESIGN, SETTING, AND PARTICIPANTS

A retrospective review of robotic (R)-RPLND performed by a single surgeon from April 2008 to October 2014 using two approaches was performed. In total, 20 procedures in 19 patients were evaluated. Eleven men had clinical stage (CS) I disease, six had CS II, one of whom had prior chemotherapy, and two had CS III disease and had also undergone previous chemotherapy.

SURGICAL PROCEDURE

A lateral robotic approach was initially used; however, a supine robotic approach was developed to allow for bilateral dissection in one setting without repositioning. Template dissection with nerve sparing was performed for CS I patients and full bilateral dissection for patients with CS II or higher disease and for those who had active disease according to intraoperative frozen section results.

OUTCOME MEASUREMENTS

Mean operative time, estimated blood loss, hospital stay, and lymph node count were retrospectively reviewed, as was the presence of recurrence or the need for adjuvant therapy over median follow-up of 49 mo (interquartile range [IQR] 37.4-70.5). Intraoperative and postoperative complications were also reviewed.

RESULTS AND LIMITATIONS

R-RPLND was performed successfully in 20 procedures in 19 patients; 11 were performed from a lateral approach and nine from a supine approach. The median operating time (available for 19 of 20 cases) was 293min (IQR 257.5-317). Median estimated blood loss and length of stay were 50ml (IQR 50-100) and 1 d (IQR 1-2), respectively. Some 70% (14/20) of patients were discharged after one night. The median lymph node yield was 19.5 (IQR 13.8-27. 3). Eleven patients had pathologic stage I disease, and eight had residual disease on pathology. There was one ureteral transection that was repaired robotically at the time of surgery with no long-term sequelae. There were no open conversions or transfusions. Two patients had ejaculatory dysfunction following bilateral RPLND. There has been no evidence of retroperitoneal disease recurrence during the follow-up period. Limitations include the retrospective nature of the study and the single surgeon experience.

CONCLUSIONS

R-RPLND can be successfully performed and provides improved visualization and dexterity over conventional laparoscopy. Patients experience significantly reduced morbidity and the nodal yield is comparable to open surgical techniques.

PATIENT SUMMARY

We studied our experience with robot-assisted removal of lymph nodes from the abdomen among men with testicular cancer. This method was found to be safe and effective with a very short hospital stay.

Paper tigers—Do clinical guidelines improve health care quality in patients with testicular germ cell tumors in Germany?

In Germany, germ cell tumors are characterized by a marked excess mortality, i.e. a discrepancy between the actual mortality and the mortality expected with adequate implementation of the standard therapy. Moreover, Germany not only has a significantly increased mortality in an international comparison but also shows marked regional differences in the quality of medical care. This is partly due to difficulties in implementing the standard therapy. An attempt was made to improve the quality of medical care by setting up evidence-based diagnostic and therapeutic guidelines in 1996. Contrary to expectations, however, these guidelines have thus far remained largely ineffective, their implementation being hampered by a solely passive dissemination strategy. Added to this are inadequate medical care structures in which the guidelines cannot be properly implemented because of the organizational, social and professional context. Decisive for a quality improvement in the diagnosis, therapy and care of germ cell tumor patients is active dissemination of the guidelines supplemented by a change in the care structure. It is also important to establish indicators for measuring the success of guideline implementation and to perform continuous progress monitoring in order to specifically overcome evident barriers. Future research is required to create a better theoretical basis and to develop further strategies for guideline dissemination and implementation.

Management of clinical stage I nonseminomatous germ-cell testis tumors

Nonseminomatous germ-cell tumors of the testis, the most common cancer in young adult males, are highly curable. Clinical Stage I disease represents almost a third of the patients. Three treatment strategies are currently available: surveillance, postorchiectomy chemotherapy and retroperitoneal lymph node dissection. Factors predictive of extratesticular involvement have been described, thus making it possible to tailor treatment to risk. New imaging procedures also permit staging and prediction of outcome. Decision-making is shared between the patient and his oncologist. Economic issues are better understood but should be further studied.